A Study of AUR104 in Patients with Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Status:
RECRUITING
Trial end date:
2027-01-04
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104.In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.